

Edgar Filing: VISX INC - Form DEFA14A

VISX INC  
Form DEFA14A  
May 06, 2003

SCHEDULE 14A  
(RULE 14A-101)

INFORMATION REQUIRED IN PROXY STATEMENT  
SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of  
the Securities Exchange Act of 1934

Filed by the Registrant  |  
Filed by a Party other than the Registrant  |  
Check the appropriate box:  
 Preliminary Proxy Statement  
 Confidential, for Use of the Commission Only (as permitted by  
Rule 14a-6(e)(2))  
 Definitive Proxy Statement  
 Definitive Additional Materials  
 Soliciting Material Under Rule 14a-12

VISX, INCORPORATED

-----  
(Name of Registrant as Specified In Its Charter)

-----  
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.  
 Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction  
applies: common stock, \$.01 par value per share

-----  
(2) Aggregate number of securities to which transaction applies:

-----  
(3) Per unit price or other underlying value of transaction computed  
pursuant to Exchange Act Rule 0-11 (set forth the amount on which  
the filing fee is calculated and state how it was determined):

-----  
(4) Proposed maximum aggregate value of transaction:

-----  
(5) Total fee paid:

-----  
 Fee paid previously with preliminary materials.

-----  
 Check box if any part of the fee is offset as provided by Exchange Act  
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was

Edgar Filing: VISX INC - Form DEFA14A

paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

-----  
(1) Amount Previously Paid:

-----  
(2) Form, Schedule or Registration Statement No.:

-----  
(3) Filing Party:

-----  
(4) Date Filed:  
-----

slide 1

THE LEADER IN LASER VISION CORRECTION

[VISX LOGO]

VISX  
INCORPORATED

WE MAKE THINGS CLEAR

slide 2

CAUTIONARY STATEMENTS

This presentation contains certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, forecasts, and assumptions of VISX that involve risks and uncertainties. Forward-looking statements in this letter, including statements regarding our future leadership position and financial performance, the ability to gain incremental revenue and profit from VISX procedures and reinvigorate demand for laser vision correction, and the expansion of our current market penetration, are based on information available to the Company as of the date hereof. FDA approval of CustomVue™ is expected in the second quarter of 2003, but is not certain. The Company's actual results could differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with the Company's business, which include the risk factors disclosed in the Company's most recent filings with the Securities and Exchange Commission, including VISX's Annual Report and Form 10K for the year ended December 31, 2002. The Company assumes no obligation to update the information included in this presentation, whether as a result of new information, future events or otherwise.

[VISX LOGO]

# Edgar Filing: VISX INC - Form DEFA14A

slide 3

## The Laser Vision Correction Market

[VISX LOGO]

slide 4

### Market Dynamics

- o More procedures than any other elective surgery
- o Widely advertised procedure
- o Considerable media exposure
- o Economy has impacted growth
- o New CustomVue[™] procedure offers fresh message

[VISX LOGO]

slide 5

[BAR GRAPH OMITTED]

### Consumer Confidence Impacts Market

	Q1-01	Q2-01	Q3-01	Q4-01	Q1-02	Q2-02	Q3-02	Q4-02
LASIK Procedures	415,200	369,400	286,300	274,800	355,400	314,750	253,300	252,000
Consumer Confidence	117	118.9	97	93.7	110.2	106.3	93.7	80.3

[VISX LOGO]

slide 6

[PIE CHART OMITTED]

### Consumer Interest in LVC

Respondents 18-34 years of age

May have 33%

Definitely or probably have 15%

## Edgar Filing: VISX INC - Form DEFA14A

Source: VisionWatch Survey

Consumers Want To Get Rid Of Glasses And Contacts.  
They Know They Can With LVC.

[VISX LOGO]

slide 7

VISX

- o Market Leader in Laser Vision Correction
- o Strong Financial Position
- o Poised for Growth
- o Focused on Maximizing Stockholder Return
- o Seasoned Board and Management that Understand Drivers for VISX

[VISX LOGO]

slide 8

Continued Strong Market Share

[PIE CHARTS OMITTED]

Percentage of Market Share Based on Number of Procedures Performed

2000

VISX	68%
Alcon	20%
Nidek	9%
B&L	2%
Other	1%

2001

VISX	60%
Alcon	23%
Nidek	12%
B&L	4%
Other	1%

2002

VISX	60%
Alcon	22%
Nidek	8%
B&L	8%
Other	2%

Source: MarketScope

## Edgar Filing: VISX INC - Form DEFA14A

[VISX LOGO]

slide 9

Market Leader Since 1997

[GRAPHIC OMITTED]

	Q1 96	Q3 96	Q1 97	Q3 97	Q1 98	Q3 98	Q1 99
Alcon-Summit	100%	81.9%	63.1%	39%	30%	27.2%	19.8%
Visx		18.1%	36.9%	61%	70%	72.8%	77.9%
Nidek							2.3%
LaserSight							
B & L							

[Table continued]

	Q1 00	Q3 00	Q1 01	Q3 01	Q1 02	Q3-02
Alcon-Summit	20.1%	19.5%	22.3%	19.8%	19.7%	19.6%
Visx	71.7%	67.5%	63%	61.8%	59.5%	61.1%
Nidek	7.7%	9.8%	10.6%	14.1%	14.5%	13.9%
LaserSight	0.3%	1.5%	0.8%	0.6%	1.2%	0.6%
B & L	0.2%	1.7%	3.3%	3.7%	5.1%	4.8%

Source: MarketScope

[VISX LOGO]

slide 10

Strong Financial Results

2002 Highlights

- o 20% operating income
- o \$123 million in cash
- o \$40 million in cash from operations
- o Purchased 4 million shares of stock
  - 20 million in the past 6 years

[VISX LOGO]

slide 11

Procedures Drive Business

Number of Procedures

X

Revenue  
Per Procedure

[VISX LOGO]

slide 12

CustomVue™ - A Significant Advancement in Vision Correction

WaveScan  
System

Star S4  
System

[PHOTO]

[PHOTO]

Comprehensive  
Measurement

Comprehensive  
Correction

[VISX LOGO]

slide 13

CustomVue™ Results

- o More precise correction
  - 0.01 Diopter vs. 0.25 Diopter with glasses and contacts
- o Better than 20/20 vision
  - > 70% of patients
- o Night Vision Improvement
  - Four times as many patients "very satisfied"

Potentially Better Vision Than  
Glasses or Contacts

slide 14

# Edgar Filing: VISX INC - Form DEFA14A

## CustomVueTM Adds Significant Value

[LINE GRAPH OMITTED]

Annualized Percent Conversion from Standard to Custom	Incremental Operating Profit (\$MM)
10%	\$7
20%	\$14
30%	\$21
40%	\$28
50%	\$35
60%	\$42

## Premium CustomVueTM Fee Leverages Profits

[VISX LOGO]

slide 15

### Maximizing Stockholder Value

- o Organic Growth through Technology Leadership
- o Stock Repurchase
- o Merger and Acquisition Opportunities
- o Strong Corporate Governance Practices

[VISX LOGO]

slide 16

### VISX Corporate Governance Highlights

- o No staggered board
- o Lead director leads executive sessions of the Board
- o Board meets regularly in executive sessions w/o management
- o Audit committee meets heightened audit committee independence requirements, includes financial expert
- o Independent directors on Compensation and Governance committees

## Edgar Filing: VISX INC - Form DEFA14A

- o Committees are authorized to engage advisors and counsel
- o Governance principles published in Proxy
- o Complete access to all VISX officers and employees
- o Directors will attend certified director education course

[VISX LOGO]

slide 17

Current VISX Board is the Right Board to Lead the Company

- |X| 6 of the 7 are independent directors
- |X| All have public company board experience
- |X| All with senior level management experience at a NYSE or Nasdaq listed company

The VISX Board has decades of experience in the medical and ophthalmic industries and significant mergers and acquisitions experience

[VISX LOGO]

slide 18

Keith Meister

- o Limited experience:
  - J Net, formerly JackPot, recently delisted from the NYSE
  - Terminated as fund manager at J Net
  - 2 year stint as junior analyst at Lazard Freres
- o Icahn's employee
- o Public Board Experience: FOUR MONTHS on an Icahn Controlled Company

Board Work is Real Work

[VISX LOGO]

slide 19

Icahn History Overview

Icahn's First Attempt



## Edgar Filing: VISX INC - Form DEFA14A

- o 12/05/00 - Announces intent to nominate 6 to VISX Board, including Sam Waksal
- o 04/18/01 - Challenges VISX to conduct an open auction
- o 04/20/01 - Offers to BUY at \$32 per share

### VISX Acts In Best Interest of All Stockholders

- o 04/23/01 - Invites Icahn to present formal offer
- o 04/26/01 - Adopts chewable pill for offers at or above \$32 per share
- o 04/26/01 - ISS recommends vote for VISX director nominees

### Icahn Withdraws from Proxy Contest

[VISX LOGO]

slide 20

### Icahn History Overview cont'd

#### Icahn's Second Attempt

- o 11/20/01 - Announces intent to nominate 5 individuals to VISX Board  
Icahn Withdraws Once Again

#### Icahn's Third Attempt

- o 04/10/03 - Icahn nominates Keith Meister to VISX Board

[VISX LOGO]

slide 21

### Board Nominees

#### ELIZABETH H. DAVILA

Director since: 1995

Age: 58

Chairman of the Board, President and Chief Executive Officer, VISX

Member of Board of Directors of Nugen Technologies, Inc.  
Prior Board Membership: VidaMed, Inc.

Previously: President, COO of VISX (1999 to 2001). Executive Vice President (1995 to 1999). Senior management positions with Syntex Corporation (1977 to 1994).

#### LAUREEN DE BUONO

Director since: 2003

Age: 45

Member of Board of Directors of INVIVO Corporation.

Previously: Executive VP, CFO of Critical Path (2001 to 2003). Managing Director for various public and private companies (2000 to 2001). CFO, COO

## Edgar Filing: VISX INC - Form DEFA14A

Executive VP, COO, CFO of Resound Corporation (1998 to 1999). Executive Vice President, Nellcor Puritan Bennett (1992 to 1998). Division and Corporate Controller (1982 to 1992).

[VISX LOGO]

slide 22

GLENDON E. FRENCH  
Director since: 1995

Prior Board Membership: Applied Immune Sciences, Inc.

Age: 69

Previously: CEO of Imagyn Medical, Inc. (1992 to 1994). Chairman and CEO, director of Applied Immune Sciences, Inc. (1989 to 1992). Chairman and Education Services Sector of ARA Services, Inc. (1982 to 1988). Director of Health Care (1972 to 1982).

JOHN W. GALIARDO  
Director since: 1996

Member of the Board of Directors of MedSource Technologies, Inc. Chairman of Becton Dickinson & Co.

Age: 69

Previously: VP and General Counsel of Becton Dickinson (1977 to 1982). Chairman of E.R. Squibb & Sons. Associated with the law firm of Dewey, Ballantine, Taft, Fierman, Heder, Handler & Lander, New York City. Former Chairman of the Health Industry Manufacturers Association.

[VISX LOGO]

slide 23

JAY T. HOLMES  
Director since: 1999

Member of the Advisory Board of Directors of Rochester Energy Group, Bausch & Lomb, Finger Lakes Blue Cross/Blue Shield, Rochester Energy Services, Inc.

Age: 60

Previously: Executive VP, Chief Administrative Officer at Bausch & Lomb (1993 to 1995). Senior Vice President, Chief Administrative Officer at Bausch & Lomb (1983 to 1993). VP, General Counsel at Bausch & Lomb (1986 to 1996). Board of Directors of Bausch & Lomb (1986 to 1996).

GARY S. PETERSMEYER  
Director since: 2001

Chairman of the Board for the Positive Coaching Alliance formed October 2001. Prior Board Membership: Cardiometrix

Age: 56

Previously: Interim CEO of Eunoe Corporation (2002). Consultant to several companies, including Inamed Corp (1999 to 2000). President, COO, director of Eunoe Corporation (2001 to 2002). President, COO, director of Collagen Aesthetics Inc. and Collagen Corporation (1986 to 1990). President, CEO, Health Care at Syntex Corporation (1990 to 1995). President, CEO, Ophthalmic Products Division of CooperVision (1982 to 1986). Series of positions in research, and marketing for Syntex Corporation (1976 to 1982).

[VISX LOGO]

Edgar Filing: VISX INC - Form DEFA14A

slide 24  
RICHARD B. SAYFORD

Director since: 1995

Chairman of the Board of Directors of HCA -- HealthOne, L.L.C. Pr  
American Fiber Optics, Laser Technologies

Age: 72

Previously: Founding investor of MCI Communications Co. Served as  
Directors of MCI (1980 to 1998). Former President of Amdahl Inter  
of Amdahl Corporation. Held various management positions with IBM

[VISX LOGO]

slide 25

VISX HAS THE RIGHT TEAM IN PLACE TO:

- o GROW THE COMPANY AND
- o CREATE LONG-TERM VALUE

FOR ALL OUR STOCKHOLDERS

[VISX LOGO]

slide 26

THE LEADER IN LASER VISION CORRECTION

[VISX LOGO]

VISX  
INCORPORATED

WE MAKE THINGS CLEAR